134 related articles for article (PubMed ID: 7351495)
21. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Tanew A; Ortel B; Rappersberger K; Hönigsmann H
J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
[TBL] [Abstract][Full Text] [Related]
22. Photochemotherapy in psoriasis-clinical response and 8-MOP plasma concentrations at two dose levels.
Andrew E; Nilsen A; Thune P; Wiik I
Clin Exp Dermatol; 1981 Nov; 6(6):591-600. PubMed ID: 7042134
[No Abstract] [Full Text] [Related]
23. Initial photochemotherapy of psoriasis with orally administered 8-methoxypsoralen and longwave ultraviolet light (PUVA).
Siddiqui AH; Cormane RH
Br J Dermatol; 1979 Mar; 100(3):247-50. PubMed ID: 435382
[TBL] [Abstract][Full Text] [Related]
24. Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.
John BA; Chasseaud LF; Wood SG; Forlot P
Xenobiotica; 1992 Nov; 22(11):1339-51. PubMed ID: 1492426
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of 8-methoxypsoralen in two different drug preparations: correlation with photosensitivity and UV-A dose requirements for photochemotherapy.
Hönigsmann H; Jaschke E; Nitsche V; Brenner W; Rauschmeier W; Wolff K
J Invest Dermatol; 1982 Oct; 79(4):233-6. PubMed ID: 7130741
[TBL] [Abstract][Full Text] [Related]
26. Plasma 8-methoxypsoralen concentrations in photochemotherapy of psoriasis.
Stevenson IH; Kenicer KJ; Johnson BE; Frain-Bell W
Br J Dermatol; 1981 Jan; 104(1):47-51. PubMed ID: 7459268
[TBL] [Abstract][Full Text] [Related]
27. [Determination of 8-methoxypsoralen in mouse plasma by high performance liquid chromatography and its application to pharmacokinetic study].
Wu TW; Cui R; Zhang BX
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 50(5):792-796. PubMed ID: 30337737
[TBL] [Abstract][Full Text] [Related]
28. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
Berg M; Ros AM
Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
[TBL] [Abstract][Full Text] [Related]
29. The mitotic index in psoriatic plaques and their response to PUVA therapy.
Goldberg LH; Cox AJ; Abel EA
Br J Dermatol; 1980 Apr; 102(4):401-5. PubMed ID: 7387882
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of 8-methoxypsoralen after topical paint PUVA.
Pham CT; Koo JY
J Am Acad Dermatol; 1993 Mar; 28(3):460-6. PubMed ID: 8445063
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo study of 5-methoxypsoralen skin concentration after topical application.
Colombo G; Zucchi A; Allegra F; Colombo P; Zani F; Santi P
Skin Pharmacol Appl Skin Physiol; 2003; 16(2):130-6. PubMed ID: 12637789
[TBL] [Abstract][Full Text] [Related]
32. Photochemotherapy of psoriasis (PUVA) without specialized equipment.
Petrozzi JW; Kligman AM
Arch Dermatol; 1978 Mar; 114(3):387-90. PubMed ID: 629574
[TBL] [Abstract][Full Text] [Related]
33. Validation of a microdialysis-gas chromatographic-mass spectrometric method to assess 8-methoxypsoralen in psoriatic patient dermis.
Leveque N; Muret P; Mary S; Bérard M; Makki S; Pierre Kantelip J; Humbert P
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(1):119-27. PubMed ID: 12383487
[TBL] [Abstract][Full Text] [Related]
34. 8-Methoxypsoralen-DNA adducts in patients treated with 8-methoxypsoralen and ultraviolet A light.
Yang XY; Gasparro FP; DeLeo VA; Santella RM
J Invest Dermatol; 1989 Jan; 92(1):59-63. PubMed ID: 2642513
[TBL] [Abstract][Full Text] [Related]
35. Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.
Muret P; Humbert P; Makki S; Bechtel P; Urien S; Tillement JP
Arch Dermatol Res; 1993; 285(5):287-90. PubMed ID: 8379689
[TBL] [Abstract][Full Text] [Related]
36. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
Nitsche V; Raff M; Bardach H
Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
[TBL] [Abstract][Full Text] [Related]
37. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of 8-methoxypsoralen 2 hours after oral administration.
Steiner I; Prey T; Gschnait F; Washüttl J; Greiter F
Acta Derm Venereol; 1978; 58(2):185-8. PubMed ID: 76402
[TBL] [Abstract][Full Text] [Related]
39. Clinical study of a new preparation of 8-methoxypsoralen in photochemotherapy.
el-Mofty AM; el-Sawalhy H; el-Mofty M
Int J Dermatol; 1994 Aug; 33(8):588-92. PubMed ID: 7960360
[TBL] [Abstract][Full Text] [Related]
40. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
